PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18191995-0	2008	Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells.	Cisplatin	0-9	TNF superfamily member 10	Homo sapiens	34-39	
18191995-6	2008	Real-time PCR was used for gene expression analysis of the TRAIL receptor dr5 and the pro-apoptotic bax following treatment with cisplatin.	Cisplatin	129-138	TNF superfamily member 10	Homo sapiens	59-64	
18191995-8	2008	This effect was enhanced following pre-treatment with cisplatin (25 microM) for 2 or 18 h. Moreover, pre-treatment with cisplatin decreased the maximal effective dose of TRAIL from 100 ng/ml to as low as 3 ng/ml in both cell lines.	Cisplatin	54-63	TNF superfamily member 10	Homo sapiens	170-175	
18191995-8	2008	This effect was enhanced following pre-treatment with cisplatin (25 microM) for 2 or 18 h. Moreover, pre-treatment with cisplatin decreased the maximal effective dose of TRAIL from 100 ng/ml to as low as 3 ng/ml in both cell lines.	Cisplatin	120-129	TNF superfamily member 10	Homo sapiens	170-175	
18191995-10	2008	While the level of p53 expression enhanced both the death-inducing and TRAIL-sensitizing effects of cisplatin, TRAIL-induced cell death was found to occur independent of p53.	Cisplatin	100-109	TNF superfamily member 10	Homo sapiens	71-76	
18191995-11	2008	CONCLUSIONS: These data suggest that the efficacy of cisplatin in GCT cells can be enhanced through combinatorial treatment with TRAIL.	Cisplatin	53-62	TNF superfamily member 10	Homo sapiens	129-134	
18191995-13	2008	Combinatorial treatment of GCTs with cisplatin and TRAIL may provide an efficacious addition to cisplatin-based regimens.	Cisplatin	96-105	TNF superfamily member 10	Homo sapiens	51-56